Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab.
Jaren LernerMiguel Michel OcampoConstantin A DasanuPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
EGFR inhibitors are potential avenues for the subsequent lines of therapy in metastatic or relapsed/refractory anal cancer. Prospective clinical trials of cetuximab alone or in combination with other agents are warranted in this setting in the future.
Keyphrases
- squamous cell
- small cell lung cancer
- papillary thyroid
- clinical trial
- acute lymphoblastic leukemia
- squamous cell carcinoma
- acute myeloid leukemia
- multiple myeloma
- diffuse large b cell lymphoma
- hodgkin lymphoma
- metastatic colorectal cancer
- locally advanced
- epidermal growth factor receptor
- case report
- randomized controlled trial
- lymph node metastasis
- wild type
- bone marrow
- cell therapy
- chemotherapy induced